Literature DB >> 23649946

Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema.

Leah A Owen1, M Elizabeth Hartnett.   

Abstract

Diabetic macular edema (DME) is a significant cause of vision loss and represents an important clinical and public health problem. It is characterized by breakdown of the blood retinal barrier with fluid accumulation in the sub-retinal and intra-retinal spaces. Although several hypotheses exist for the causes of diabetic macular edema, specific molecular mechanisms remain unclear. Current thinking includes the role of vascular endothelial growth factor (VEGF) and inflammatory cytokines in vascular permeability. We review studies showing a relationship between elevated aqueous VEGF, monocyte chemoattractant protein -1, interleukin 6, or interleukin 8 in association with DME and as predictors of DME. The presence of mediators in both the angiogenesis and inflammatory pathways data suggest a multifactorial model for the development of DME. Further studies targeting individual cytokine activity will be important to our understanding of the pathogenesis and treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649946      PMCID: PMC3703469          DOI: 10.1007/s11892-013-0382-z

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  36 in total

1.  Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Hidetaka Noma; Tatsuya Mimura; Tetsuji Yamashita; Sadao Hori
Journal:  Am J Ophthalmol       Date:  2002-01       Impact factor: 5.258

Review 2.  Role of vascular endothelial growth factor in diabetic vascular complications.

Authors:  L P Aiello; J S Wong
Journal:  Kidney Int Suppl       Date:  2000-09       Impact factor: 10.545

Review 3.  Diabetic retinopathyA clinical update.

Authors:  M Porta; F Bandello
Journal:  Diabetologia       Date:  2002-11-16       Impact factor: 10.122

4.  Macular grid photocoagulation. An experimental study on the primate retina.

Authors:  D J Wilson; D Finkelstein; H A Quigley; W R Green
Journal:  Arch Ophthalmol       Date:  1988-01

5.  Intravitreal triamcinolone for refractory diabetic macular edema.

Authors:  Adam Martidis; Jay S Duker; Paul B Greenberg; Adam H Rogers; Carmen A Puliafito; Elias Reichel; Caroline Baumal
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion.

Authors:  Won June Lee; Min Ho Kang; Mincheol Seong; Hee Yoon Cho
Journal:  Br J Ophthalmol       Date:  2012-08-28       Impact factor: 4.638

7.  Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Hidetaka Noma; Erika Shimizu; Tatsuya Mimura; Sadao Hori
Journal:  J Cataract Refract Surg       Date:  2002-08       Impact factor: 3.351

8.  Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1985-12

9.  Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema.

Authors:  Hideharu Funatsu; Hidetoshi Yamashita; Tomohiro Ikeda; Tatsuya Mimura; Shuichiro Eguchi; Sadao Hori
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

10.  Unusual neutrophil infiltration under the soft contact lens in a patient with Behçet's disease.

Authors:  Noriyasu Hashida; Nobuyuki Ohguro; Shuji Yamamoto; Yayoi Nakagawa; Yasuo Tano
Journal:  Jpn J Ophthalmol       Date:  2003 Sep-Oct       Impact factor: 2.447

View more
  23 in total

1.  Study of aqueous cytokines in patients with different patterns of diabetic macular edema based on optical coherence tomography.

Authors:  Sabyasachi Bandyopadhyay; Samir Kumar Bandyopadhyay; Mita Saha; Abhik Sinha
Journal:  Int Ophthalmol       Date:  2017-02-03       Impact factor: 2.031

2.  An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy.

Authors:  Fernanda Pacella; Maria Rosaria Romano; Paolo Turchetti; Giovanna Tarquini; Anna Carnovale; Antonella Mollicone; Alessandra Mastromatteo; Elena Pacella
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

3.  Diabetic retinopathy with extensively large area of capillary non-perfusion: characteristics and treatment outcomes.

Authors:  Zijing Huang; Kunliang Qiu; Jingsheng Yi; Hongjie Lin; Dezhi Zheng; Dingguo Huang; Guihua Zhang; Haoyu Chen; Jianlong Zheng; Yifan Wang; Danqi Fang; Weiqi Chen
Journal:  BMC Ophthalmol       Date:  2022-07-04       Impact factor: 2.086

4.  Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema.

Authors:  George G Bastakis; Dimitris Dimopoulos; Anastasios Stavrakakis; George Pappas
Journal:  Eye (Lond)       Date:  2018-10-09       Impact factor: 3.775

5.  Systemic and vitreous biomarkers - new insights in diabetic retinopathy.

Authors:  Bernardete Pessoa; João Heitor; Constança Coelho; Magdalena Leander; Pedro Menéres; João Figueira; Angelina Meireles; Melo Beirão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-24       Impact factor: 3.535

6.  Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant.

Authors:  Dominik Zalewski; Dorota Raczyńska; Krystyna Raczyńska
Journal:  Mediators Inflamm       Date:  2014-02-10       Impact factor: 4.711

7.  A potential novel therapeutic target in diabetic retinopathy: a chemokine receptor (CCR2/CCR5) inhibitor reduces retinal vascular leakage in an animal model.

Authors:  Finny Monickaraj; Sreenivasa R Oruganti; Paul McGuire; Arup Das
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-08-20       Impact factor: 3.117

Review 8.  The evolving treatment options for diabetic macular edema.

Authors:  Atul Jain; Neeta Varshney; Colin Smith
Journal:  Int J Inflam       Date:  2013-09-09

9.  Intravitreal Injection of Ozurdex(®) Implant in Patients with Persistent Diabetic Macular Edema, with Six-Month Follow-Up.

Authors:  Fernanda Pacella; Adriana Francesca Ferraresi; Paolo Turchetti; Tommaso Lenzi; Rosalia Giustolisi; Andrea Bottone; Valeria Fameli; Maria Rosaria Romano; Elena Pacella
Journal:  Ophthalmol Eye Dis       Date:  2016-04-28

10.  The Neuroprotective Effect of Rapamycin as a Modulator of the mTOR-NF-κB Axis during Retinal Inflammation.

Authors:  Tomohiro Okamoto; Yoko Ozawa; Mamoru Kamoshita; Hideto Osada; Eriko Toda; Toshihide Kurihara; Norihiro Nagai; Kazuo Umezawa; Kazuo Tsubota
Journal:  PLoS One       Date:  2016-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.